Clinical Trial

Impact of Fusobacterium Nucleatum on Response to Anti-EGFR Therapy in Metastatic Colorectal Cancer

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This retrospective observational cohort study investigates the association between the intratumoral burden of the bacterium Fusobacterium nucleatum (Fn) and the efficacy of anti-EGFR targeted therapies (cetuximab or panitumumab) in patients with RAS wild-type metastatic colorectal cancer (mCRC). Bacterial quantification will be performed using droplet digital polymerase chain reaction (ddPCR) on formalin-fixed, paraffin-embedded (FFPE) tissue samples, comprising an estimated cohort of 500 patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-26.
Trial Details
NCT Number NCT07619859
Lead Sponsor Barretos Cancer Hospital
Conditions Metastatic Colorectal Cancer (CRC)
Enrollment 500 participants
Start Date 2024-07-05
Primary Completion 2027-12-10 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-04